Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Person

James Eugene

Tracked across 1 events · 21 articles · First seen Sep 08, 2026 · Last active Sep 08, 2026

Sentiment
-40
Attention
6
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
6 -40
Business
Novartis announced on September 8, 2026 that its Phase III HARBOR study of del-desiran, an antibody oligonucleotide conjugate for myotonic dystrophy type 1 (DM1), failed to show statistically significant improvement versus placebo on the primary…
Impact: Analyst at Verso Investment Management, provided critical commentary on the trial failure.
Sep 08, 2026 · 21 articles
ERGEN INTELLIGENCE
Track James Eugene live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.